论文部分内容阅读
目的:研究人参皂苷Rb1通过抑制自体静脉移植物增殖细胞核抗原(PCNA)的表达,进而抑制移植物内膜平滑肌细胞过度增生的作用。方法:45只新西兰大白兔随机分为实验组、模型组、对照组,每组15只。应用no-touch外科技术获取颈外静脉后,采用外翻连续缝合方法将颈外静脉吻合至颈总动脉,建立静脉移植桥的动物模型。4周后利用苏木精-伊红染色观察移植静脉血管内膜形态及厚度变化,RT-PCR检测静脉移植血管中PCNA mRNA的表达。结果:光镜下结果显示:移植4周后,实验组、模型组和对照组移植血管的内膜厚度分别为(41.57±2.43)、(73.76±7.83)和(11.38±0.71)μm,各组间差异有统计学意义(P<0.05),移植静脉内膜/中膜厚度比分别为(1.21±0.09)、(1.44±0.12)和(0.28±0.07),各组间差异有统计学意义(P<0.05);移植4周后的实验组、模型组和对照组PCNA mRNA相对含量比值分别是(0.942±0.004)、(0.756±0.003)和(0.574±0.002),各组间差异有统计学意义(P<0.05)。结论:人参皂苷Rb1能够抑制移植血管PCNA mRNA的过度表达,进而有效减轻移植血管内膜增生导致的再狭窄,延长静脉血管桥的使用寿命。
Objective: To study the effect of ginsenoside Rb1 on the proliferation of rat intima-smooth muscle cells by inhibiting the expression of proliferating cell nuclear antigen (PCNA) in autologous vein grafts. Methods: Forty five New Zealand white rabbits were randomly divided into experimental group, model group and control group with 15 rats in each group. After the external jugular vein was obtained by no-touch surgical technique, the external jugular vein was anastomosed to the common carotid artery by everted continuous suture to establish the animal model of vein graft. After 4 weeks, hematoxylin-eosin staining was used to observe the morphology and thickness of the vein intima. The expression of PCNA mRNA was detected by RT-PCR. Results: Under the light microscope, the thickness of intima in the experimental group, model group and control group were (41.57 ± 2.43), (73.76 ± 7.83) and (11.38 ± 0.71) μm, respectively (1.21 ± 0.09), (1.44 ± 0.12) and (0.28 ± 0.07), respectively, with significant difference between the two groups (P <0.05) P <0.05). The relative contents of PCNA mRNA in the experimental group, model group and control group after 4 weeks of transplantation were (0.942 ± 0.004), (0.756 ± 0.003) and (0.574 ± 0.002), respectively Significance (P <0.05). CONCLUSION: Ginsenoside Rb1 can inhibit the overexpression of PCNA mRNA in transplanted blood vessels, which can effectively reduce the restenosis caused by intimal hyperplasia and prolong the service life of venous bridge.